FDA WARNING_LETTER - CP Pharmaceuticals, Ltd. - July 29, 2010

On October 29, 2010, the FDA issued a Warning Letter to CP Pharmaceuticals, Ltd. following a July 22-29, 2010 inspection of their Wrexham, UK pharmaceutical manufacturing facility. The inspection revealed significant violations of Current Good Manufacturing Practice (CGMP) regulations for Finished Pharmaceuticals (21 CFR Parts 210 and 211), rendering their drug products adulterated.

Key violations included: 1. **Aseptic Processing Control Deficiencies (21 CFR § 211.42(c)):** Lack of documentary evidence for in-situ air pattern analysis (smoke studies) in critical areas, failure to ensure aseptic conditions in production rooms and equipment, inadequate environmental monitoring practices (e.g., mold contamination in Class 100 room, poor wall conditions in freeze dryer room), and inadequate aseptic techniques by operators, including unmonitored personnel sampling. 2. **Inadequate Investigations (21 CFR § 211.192):** Failure to routinely perform species identification of yeast and molds, lack of raw data for a failed November 2009 media fill, and absence of challenge testing for sterility media with environmental isolates. 3. **Insufficient Laboratory Controls (21 CFR § 211.160(b)):** Incomplete or unavailable validation data for several laboratory methods (e.g., total viable aerobic